Anti-CD20 IgGA treatment of tumor bearing mice (transgenic for CD89 on CD14+ myeloid cells) led to an improved regression of tumors in comparison to IgG or IgA, in a CD89-dependent manner. This evidence concerns the gene FCAR and neoplasm.